TY - JOUR
T1 - In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation
AU - Swijnenburg, Rutger Jan
AU - Schrepfer, Sonja
AU - Cao, Feng
AU - Pearl, Jeremy I.
AU - Xie, Xiaoyan
AU - Connolly, Andrew J.
AU - Robbins, Robert C.
AU - Wu, Joseph C.
PY - 2008/12
Y1 - 2008/12
N2 - Embryonic stem cell (ESC)-based transplantation is considered a promising novel therapy for a variety of diseases. This is bolstered by the suggested immune-privileged properties of ESCs. In this study, we used in vivo bioluminescent imaging (BLI) to non-invasively track the fate of transplanted murine ESCs (mESCs), which are stably transduced with a double fusion reporter gene consisting of firefly luciferase (FLuc) and enhanced green fluorescent protein (eGFP). Following syngeneic intramuscular transplantation of 1 × 106 mESCs, the cells survived and differentiated into teratomas. In contrast, allogeneic mESC transplants were infiltrated by a variety of inflammatory cells, leading to rejection within 28 days. Acceleration of rejection was observed when mESCs were allotransplanted following prior sensitization of the host. Finally, we demonstrate that the mESC derivatives were more rapidly rejected compared to undifferentiated mESCs. These data show that mESCs do not retain immune-privileged properties in vivo and are subject to immunological rejection as assessed by novel molecular imaging approaches.
AB - Embryonic stem cell (ESC)-based transplantation is considered a promising novel therapy for a variety of diseases. This is bolstered by the suggested immune-privileged properties of ESCs. In this study, we used in vivo bioluminescent imaging (BLI) to non-invasively track the fate of transplanted murine ESCs (mESCs), which are stably transduced with a double fusion reporter gene consisting of firefly luciferase (FLuc) and enhanced green fluorescent protein (eGFP). Following syngeneic intramuscular transplantation of 1 × 106 mESCs, the cells survived and differentiated into teratomas. In contrast, allogeneic mESC transplants were infiltrated by a variety of inflammatory cells, leading to rejection within 28 days. Acceleration of rejection was observed when mESCs were allotransplanted following prior sensitization of the host. Finally, we demonstrate that the mESC derivatives were more rapidly rejected compared to undifferentiated mESCs. These data show that mESCs do not retain immune-privileged properties in vivo and are subject to immunological rejection as assessed by novel molecular imaging approaches.
UR - http://www.scopus.com/inward/record.url?scp=49149129623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49149129623&partnerID=8YFLogxK
U2 - 10.1089/scd.2008.0091
DO - 10.1089/scd.2008.0091
M3 - Article
C2 - 18491958
AN - SCOPUS:49149129623
SN - 1547-3287
VL - 17
SP - 1023
EP - 1029
JO - Stem Cells and Development
JF - Stem Cells and Development
IS - 6
ER -